Visão geral da empresa
A clinical-stage biopharmaceutical entity, IN8bio, Inc. dedicates its operational resources to the discovery, development, and commercialization of gamma-delta T cell product candidates designed for the treatment of cancer and autoimmune diseases. The company operates within the Healthcare sector, specifically the Biotechnology industry, where capital intensity and significant research and development expenditures are standard characteristics of the business model. IN8bio maintains a market capitalization of $14.08M and employs a workforce of 17 individuals to execute its strategic initiatives. These financial metrics indicate that the company is a micro-cap entity with limited current revenue generation, a position typical for early-stage biotechnology firms that prioritize asset accumulation and clinical trial progression over immediate profitability.
Saúde financeira
The company reports a Net Income (TTM) of $-19,440,000 and an EBITDA of $-18,090,000, while specific Revenue (TTM) data is not available in the current reporting period. The substantial gap between the reported net income and EBITDA, both of which are negative, reveals a cost structure heavily influenced by non-operating expenses or significant adjustments to net income that occur in addition to core operational burn rates. Free Cash Flow stands at $-5,547,125, indicating that the company is currently burning cash to fund its operations and clinical programs rather than generating liquidity from its activities. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which reflects a stage of development where revenue recognition is either negligible or insufficient to cover the cost of goods sold and operating expenses in the traditional sense. Despite the negative income, the company holds $27.09M in cash against $2.78M in debt, resulting in a Debt to Equity ratio of 10.10, suggesting a balance sheet that is leveraged in terms of the ratio but possesses significant absolute liquidity due to the cash reserve. The Current Ratio is 8.82, a figure that indicates robust short-term liquidity and a strong ability to meet obligations with current assets. Return on Equity is -92.5% and Return on Assets is -46.6%, metrics that reveal that management is currently reducing equity and asset bases relative to net income, a common phenomenon in growth-stage biotech companies where losses are incurred to build future value.
Avaliação de valorização
The Trailing Twelve Months P/E Ratio is N/A, while the Forward P/E is -0.95; this disparity implies that earnings are currently negative and the market is attempting to value the stock based on anticipated future earnings trajectory rather than current profitability. The Price to Book ratio is 0.51, indicating that the market values the company's equity at less than its book value, suggesting a market discount often associated with high-risk biotechnology assets or specific concerns regarding the recoverability of assets. The Price to Sales ratio is N/A, and the EV/EBITDA stands at 0.56, metrics that suggest the company is being valued on enterprise value multiples that do not yet reflect profitable operations but rather potential future value upon clinical success. The 52-Week High is $5.82 and the 52-Week Low is $1.17, placing the stock's recent trading activity at the lower end of its historical range relative to the specified high. The Beta value is 0.04, a figure that indicates the stock's price volatility is significantly lower than the broader market, likely due to a lack of trading volume or specific institutional holding patterns rather than fundamental stability.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, meaning there is no comparable year-over-year data to determine if earnings are growing faster or slower than revenue in the traditional sense. As a non-dividend payer with a Dividend Yield of N/A and a Payout Ratio of 0.0%, the company does not distribute income to shareholders, implying that it reinvests all available earnings and cash reserves into research and development activities. The overall growth and income profile is characterized by a reliance on capital markets for funding rather than organic revenue growth or dividend income generation. The absence of dividend payouts and the presence of negative earnings growth metrics highlight a strategic focus on long-term product commercialization rather than short-term shareholder returns.